Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

3,3’-Diindolylmethane Exhibits Significant Metabolism After Oral Dosing in Humans

Journal Article · · Drug Metabolism and Disposition
 [1];  [1];  [1];  [1];  [1];  [1];  [1];  [2];  [1];  [3];  [1];  [1];  [1]
  1. Oregon State University
  2. BATTELLE (PACIFIC NW LAB)
  3. University of Arizona
+ Show Author Affiliations

3,3’-Diindolylmethane (DIM), a major phytochemical derived from ingestion of cruciferous vegetables such as Brussels sprouts, is also a dietary supplement. In preclinical models, DIM is an effective cancer chemopreventive agent and has been studied in a number of clinical trials. Previous pharmacokinetic studies in preclinical and clinical models have not reported DIM metabolites in plasma or urine following oral dosing and the pharmacological actions of DIM on target tissues is assumed to be solely via the parent compound. Seven subjects (6 males and 1 female) ranging from 26-65 years of age, on a cruciferous vegetable-restricted diet prior to and during the study, took 2 BioResponse-DIM® 150 mg capsules (45.3 mg DIM/capsule) in the evening for one week with a final dose the morning of the first blood draw. A complete time course was performed with plasma and urine collected over 48 hours and analyzed by UPLC-MS/MS. In addition to parent DIM, two mono-hydroxylated (2-ox- and 3-methylenehydroxy-DIM) and 1 dihydroxylated (3-methylenehydroxy-2-ox-DIM) metabolites, along with their sulfate and glucuronide conjugates, were present in both plasma and urine. The results reported here are indicative of significant phase 1 and phase 2 metabolism and differ from previous pharmacokinetic studies in rodents and humans which reported only parent DIM present following oral administration.

Research Organization:
Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC05-76RL01830
OSTI ID:
1827145
Report Number(s):
PNNL-SA-158910
Journal Information:
Drug Metabolism and Disposition, Vol. 49, Issue 8
Country of Publication:
United States
Language:
English

References (50)

Molecular Targets and Anticancer Potential of Indole-3-Carbinol and Its Derivatives June 2005
Cruciferous Vegetable Intake and Cancer Prevention: Role of Nutrigenetics: Fig. 1 March 2009
Physiological Modeling of Formulated and Crystalline 3,3′-Diindolylmethane Pharmacokinetics Following oral Administration in mice May 2004
Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention December 2015
Bioavailability and new biomarkers of cruciferous sprouts consumption October 2017
Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate June 2002
Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. November 1991
High-performance liquid chromatographic analysis of anticarcinogenic indoles in Brassica oleracea January 1987
Structure—activity relationships of dietary indoles: A proposed mechanism of action as modifiers of xenobiotic metabolism July 1987
Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study August 2010
The Pneumotoxin 3-Methylindole Is a Substrate and a Mechanism-Based Inactivator of CYP2A13, a Human Cytochrome P450 Enzyme Preferentially Expressed in the Respiratory Tract July 2009
Pilot Study: Effect of 3,3′-Diindolylmethane Supplements on Urinary Hormone Metabolites in Postmenopausal Women With a History of Early-Stage Breast Cancer November 2004
Gut dysbiosis induced by cardiac pressure overload enhances adverse cardiac remodeling in a T cell-dependent manner October 2020
The Brassica-derived phytochemical indolo[3,2-b]carbazole protects against oxidative DNA damage by aryl hydrocarbon receptor activation February 2016
Indole-3-Carbinol and 3-3′-Diindolylmethane Antiproliferative Signaling Pathways Control Cell-Cycle Gene Transcription in Human Breast Cancer Cells by Regulating Promoter–Sp1 Transcription Factor Interactions July 2003
Urinary 3,3′-Diindolylmethane: A Biomarker of Glucobrassicin Exposure and Indole-3-Carbinol Uptake in Humans December 2013
Research on cruciferous vegetables, indole-3-carbinol, and cancer prevention: A tribute to Lee W. Wattenberg May 2016
Role of Mouse Cytochrome P450 Enzymes of the Cyp2abfgs Subfamilies in the Induction of Lung Inflammation by Cigarette Smoke Exposure August 2019
The cancer chemopreventive actions of phytochemicals derived from glucosinolates May 2008
Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis March 2007
CXCR4 and CXCL12 down-regulation: A novel mechanism for the chemoprotection of 3,3′-diindolylmethane for breast and ovarian cancers June 2008
Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation March 1993
Targets for indole-3-carbinol in cancer prevention February 2005
Cruciferous vegetable intake and the risk of human cancer: epidemiological evidence: Conference on ‘Multidisciplinary approaches to nutritional problems’ Symposium on ‘Nutrition and health’ December 2008
Role of BioResponse 3,3′-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience October 2015
Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing February 2019
Mechanism of action of dietary chemoprotective agents in rat liver: induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism September 1997
Indole-3-Carbinol Triggers Aryl Hydrocarbon Receptor-dependent Estrogen Receptor (ER)α Protein Degradation in Breast Cancer Cells Disrupting an ERα-GATA3 Transcriptional Cross-Regulatory Loop April 2010
A Review of the Clinical Efficacy and Safety of Cruciferous Vegetable Phytochemicals June 2007
Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC–MS/MS and their pharmacokinetics in dogs February 2012
Cruciferous Vegetable Feeding Alters UGT1A1 Activity: Diet- and Genotype-Dependent Changes in Serum Bilirubin in a Controlled Feeding Trial March 2009
Comparative preclinical pharmacokinetics study of 3,3′-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon? December 2013
First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN) April 2016
Inhibitory effects of a dietary phytochemical 3,3′-diindolylmethane on the phenobarbital-induced hepatic CYP mRNA expression and CYP-catalyzed reactions in female rats July 2008
CYP1A2, GSTM1 , and GSTT1 Polymorphisms and Diet Effects on CYP1A2 Activity in a Crossover Feeding Trial October 2009
Diindolylmethane Derivatives: Potent Agonists of the Immunostimulatory Orphan G Protein-Coupled Receptor GPR84 May 2017
Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances. November 1987
Single-Dose and Multiple-Dose Administration of Indole-3-Carbinol to Women: Pharmacokinetics Based on 3,3′-Diindolylmethane December 2006
A Phase I Study of Indole-3-Carbinol in Women: Tolerability and Effects August 2005
Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3,3'-Diindolylmethane in Healthy Subjects October 2008
3,3′-Diindolylmethane, a Major Condensation Product of Indole-3-carbinol, Is a Potent Estrogen in the Rainbow Trout February 2001
Differential modulation of dibenzo[def,p]chrysene transplacental carcinogenesis: Maternal diets rich in indole-3-carbinol versus sulforaphane July 2013
Fate of 3,3‘-Diindolylmethane in Cultured MCF-7 Human Breast Cancer Cells February 2006
The anticarcinogen 3,3′-diindolylmethane is an inhibitor of cytochrome P-450 August 1995
Induction of Hepatic CYPIA by Indole-3-Carbinol in Protection Against Aflatoxin B1 Hepatocarcinogenesis in Rainbow Trout October 1995
A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen May 2017
Chemopreventive properties of 3,3′-diindolylmethane in breast cancer: evidence from experimental and human studies May 2016
Brassica Vegetables and Cancer Prevention January 1999
Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans April 2004
Indole-3-carbinol as a chemopreventive and anti-cancer agent April 2008

Similar Records

Related Subjects